Aurobindo, Cipla, Viatris to Develop Long-Acting HIV Drug

• Generic drugmakers Aurobindo Pharma, Cipla, and Viatris to develop, manufacture, and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries.

• This follows ViiV Healthcare’s extension of their voluntary licensing agreement to enable access to long-acting injectable HIV treatment.

• The announcement follows WHO’s updated guidance recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option.

• Existing licensees will be able to develop, manufacture, and supply generic versions of CAB LA for HIV-1 infection treatment in adults and adolescents.